TOP TEN perturbations for NM_000242 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000242
Selected probe(set): 207256_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000242 (207256_at) across 5339 perturbations tested by GENEVESTIGATOR:

breast cancer study 42 (metastase; lymph node) / breast cancer study 42 (metastase; liver)

Relative Expression (log2-ratio):-3.882369
Number of Samples:7 / 3
Experimental breast cancer study 42 (metastase; lymph node)
Metastatic tumor tissue obtained from the lymph node of patients with primary breast adenocarcinoma.
Control breast cancer study 42 (metastase; liver)
Metastatic tumor tissue obtained from the liver of patients with primary breast adenocarcinoma.

azathioprine study 8 (48h) / vehicle (DMSO) treated HepG2 cell sample

Relative Expression (log2-ratio):-3.8700237
Number of Samples:2 / 19
Experimental azathioprine study 8 (48h)
HepG2 cells exposed to 250?M azathioprine in DMSO solvent for 48 hours. ATC code:
Control vehicle (DMSO) treated HepG2 cell sample
HepG2 cells exposed to DMSO solvent for 48 hours.

2-(chloromethyl)pyridine hydrochloride study 1 (24h) / vehicle (DMSO) treated HepG2 cell sample

Relative Expression (log2-ratio):-3.8665419
Number of Samples:3 / 7
Experimental 2-(chloromethyl)pyridine hydrochloride study 1 (24h)
HepG2 cells exposed to 300?M 2-(chloromethyl)pyridine hydrochloride in DMSO solvent for 24 hours. ATC code:---
Control vehicle (DMSO) treated HepG2 cell sample
HepG2 cells exposed to DMSO solvent for 24 hours.

azathioprine study 7 (250uM) / vehicle (DMSO) treated HepG2 sample

Relative Expression (log2-ratio):-3.6615572
Number of Samples:3 / 21
Experimental azathioprine study 7 (250uM)
HepG2 cells treated with compound: azathioprine (250uM; CAS no.:446-86-6) for 24 hours. Azathioprine is hepatotoxic and may cause cholestasis. HepG2 cells were treated with the IC20 concentration measured after 72 hours. ATC code:
Control vehicle (DMSO) treated HepG2 sample
HepG2 cells treated with DMSO (0.5% v/v) as solvent control for 24 hours.

HCC study 3 (area A) / HCC study 3 (area C)

Relative Expression (log2-ratio):-3.6021595
Number of Samples:13 / 24
Experimental HCC study 3 (area A)
Liver tissue biopsy sample from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Tumorous sample was taken from the center of the tumor (area A). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery.
Control HCC study 3 (area C)
Liver tissue biopsy sample from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Non-tumorous sample was taken from the perilesional area of the tumor (area C). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery.

HCC study 3 (area A) / HCC study 3 (area D)

Relative Expression (log2-ratio):-3.5337343
Number of Samples:13 / 19
Experimental HCC study 3 (area A)
Liver tissue biopsy sample from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Tumorous sample was taken from the center of the tumor (area A). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery.
Control HCC study 3 (area D)
Liver tissue biopsy sample from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Non-tumorous sample was taken in an area 2-3 cm away from the tumor (area D). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery.

HCC study 3 (area A) / non-tumor liver tissue

Relative Expression (log2-ratio):-3.5304832
Number of Samples:13 / 37
Experimental HCC study 3 (area A)
Liver tissue biopsy sample from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Tumorous sample was taken from the center of the tumor (area A). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery.
Control non-tumor liver tissue
Histologically normal, healthy liver biopsy samples obtained from a clinically unaffected site from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Non-tumorous, non-malignant sample was taken from the unaffected edge of the liver (area E). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery.

4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone study 1 (10000 uM; Hep-G2) / vehicle (PBS) treated Hep-G2 cell sample

Relative Expression (log2-ratio):-3.3468962
Number of Samples:3 / 6
Experimental 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone study 1 (10000 uM; Hep-G2)
Hep-G2 cells exposed to 10000 uM 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (dissolved in PBS) for 72 hours. Cells were exposed to the chemical when 80% confluence was reached. Cells were treated with the IC10 determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (number of replicates, n = 3). ATC code:---
Control vehicle (PBS) treated Hep-G2 cell sample
Hep-G2 cells treated with vehicle (PBS) for 72 hours. Cells were exposed to the vehicle when 80% confluence was reached.

diclofenac study 6 (55uM) / vehicle (PBS) treated HepG2 sample

Relative Expression (log2-ratio):-3.0807695
Number of Samples:3 / 12
Experimental diclofenac study 6 (55uM)
HepG2 cells treated with compound: diclofenac (55uM; CAS no.:15307-86-5) for 24 hours. Diclofenac is hepatotoxic and may cause necrosis. HepG2 cells were treated with the IC20 concentration measured after 24 hours. ATC code:, ,
Control vehicle (PBS) treated HepG2 sample
HepG2 cells treated with PBS (0.5% v/v) as solvent control for 24 hours.

HCC study 20 (CDX; Hep-G2; orthotopic) / HCC study 20 (PDX; orthotopic)

Relative Expression (log2-ratio):-2.9783497
Number of Samples:5 / 11
Experimental HCC study 20 (CDX; Hep-G2; orthotopic)
Tumor tissue biopsy samples from Hep-G2 cell line-derived xenograft (CDX) orthotopically generated in SCID mice by injecting hepatocellular carcinoma cells directly into liver parenchyma. In order to establish orthotopic model, the left lobe of liver was exposed through midline abdominal incision and cells were injected directly into liver parenchyma of mice. The mice were euthanized after two weeks.
Control HCC study 20 (PDX; orthotopic)
Tumor tissue biopsy samples from patient-derived xenograft (PDX) sample orthotopically generated in SCID mice by injecting hepatocellular carcinoma cells directly into liver parenchyma. Donor tumor tissue was obtained intraoperatively during liver resection from three patients. All three patients had hepatocellular carcinoma confirmed by histology. In order to establish orthotopic model, the left lobe of liver was exposed through midline abdominal incision and cells were injected directly into liver parenchyma of mice. The mice were euthanized after two weeks.